Neuroendocrine Tumor Treatment Market

Global Neuroendocrine Tumor Treatment Market Size, Trends & Analysis - Forecasts to 2026 By Product (Somatostatin Analog (SSAs), Targeted Therapy, Chemotherapy and Others), By Indication (Lungs, Pancreas, Gastrointestinal, Others), By Site (Lungs, Pancreas, Colon, Small Intestine, Others), By Route of administration (Oral, Parenteral), By End-User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare and Others), Company Market Share Analysis, and Competitor Analysis

Category Healthcare

Format

This report was recently updated on November 17 2024 with the latest and most recent market numbers

Neuroendocrine Tumor Treatment Market Size

The global neuroendocrine tumor treatment market is projected to grow from USD 1.8 billion in 2021 to USD 2.1 billion by 2026 at a CAGR value of 5.7% from 2021 to 2026. The neuroendocrine tumour is a rare tumour that develops from specialised body cells named neuroendocrine cells. The neuroendocrine tumour develops from hormone-producing cells. It responds to nerve signals by producing and releasing hormones into the bloodstream.

Rapidly increasing incidence of neuroendocrine carcinoma, rising therapeutic applications, and growing number of research initiatives to launch advanced treatment technologies, are some of the factors supporting the growth of the neuroendocrine tumor therapy market.

As per the American Society of Clinical Oncology (ASCO) data, the prevalence of neuroendocrine tumors is increasing across the globe, though being a rare disease as it is estimated that more than 12,000 people are found to be affected by neuroendocrine tumors every year in the United States. Therefore, the increasing prevalence of neuroendocrine tumors helps in the adoption rate of the drugs for the treatment this rare disease.

High prevalence of neuropsychiatric malignancy, awareness regarding early cancer diagnosis, and an increasing number of government initiatives, the neuroendocrine tumor therapy market is expected to rise rapidly.

The development of drug repertoire and the identification of novel pharmaceuticals drugs that may reduce excess secretion endocrine system are also expected to promote the growth of the global neuroendocrine tumour therapy market over the forecast period.

Additionally, rapidly increasing number of high-end hospital and clinic, and increasing FDA drug approvals are expected to propel the market during the forecast period.

Oncology department in various healthcare settings had to adjust existing treatment plans during the Covid-19 pandemic since doctors and surgeons had to take time off owing to the outbreak. Oncology centres had to reorient their approaches to telehealth as a result of understaffing and the consequence of severe shut downs in certain countries. Due to the obvious protracted shutdown, oncology hospitalization and outpatient treatment were delayed, and follow-up assessments were rescheduled or cancelled.

global neuroendocrine tumor treatment market

Neuroendocrine Tumor Treatment Market: By Product

Based on product, the market is segmented into somatostatin analog (SSAs), targeted therapy, chemotherapy and others. During the forecast period, the market for somatostatin analog (SSAs) segment is expected to have the largest share. Improved protective measures for patients that do not want operations or invasive radiotherapy, rising cases of cancer, increasing research and development activities related cancer drugs and non-invasive therapies, are all factors driving this segment's growth. SSAs are primarily used to treat patients who have failed to respond to radiotherapy or surgery. As of 2020, many SSAs are undergoing clinical studies and are waiting for approval.

Neuroendocrine Tumor Treatment Market: By Site

Based on site, the market is segmented into lungs, pancreas, colon, small intestine, and others. The small intestine segment is expected to have the largest share in the market during the forecast period. Due to the fact that NETs are more likely to form in the gastrointestinal system, the market value for small intestine tumor treatment is expected to be the largest. As per data provided in a Novartis investor presentation in 2015, GI tumours account for about 60% of all NETs, with the small intestine tumour being one of the most prominent sites.

During the forecast period, the market for Gastrointestinal Tract (GI) is also estimated to grow at a rapid rate. The primary drivers boosting this segment include the increased frequency of neuroendocrine tumors, which primarily assault the digestive tract, rising cases of thyroid disorders, and lung cancer, and high prevalence of genetic abnormalities.

Neuroendocrine Tumor Treatment Market: By Route of Administration

Based on the route of administration, the market is segmented into oral, and parenteral. The oral segment is expected to have the largest share in the market during the forecast period. The oral mode of administrations offers simplicity of use, as compared to the parenteral mode of administration.

Neuroendocrine Tumor Treatment Market: By End-User

Based on end-user, the market is segmented into hospitals, specialty clinics, radiation centers, home healthcare and others. During the forecast period, the market for hospitals segment is expected to have the largest share. Increased awareness of gene deficient syndromes, the availability of novel techniques and infrastructure in hospital settings, and presence of health expertise will all contribute to the segment’s growth. The existence of different alternatives for NET diagnosis, as well as the deployment of established technology in hospital settings, are projected to boost the segment's growth.

asia pacific neuroendocrine tumor treatment market

Neuroendocrine Tumor Treatment Market: By Region

As per the geographical analysis, the neuroendocrine tumor treatment market can be classified into North America (the United States, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and the Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa (Saudi Arabia, United Arab Emirates, and Rest of the Middle East & Africa) and Central & South America (Brazil, Argentina, and Rest of Central and South America).

The presence of contemporary health centers, the occurrence of cancer and other diseases, and the growing preference for medications with scheduled insurance, sprouting genetic abnormalities and hormonal problems, rising geriatric population, and burgeoning prognosis are all expected to drive growth in North America.

Rising prevalence of NETs in Asia Pacific, rising government healthcare expenditure to address the substantial unmet clinical requirements, growing impact of chronic diseases such as cancer, poor diets, and rising adoption of novel drugs for cancer therapies, are some of the factors driving the growth of the APAC market.

Neuroendocrine Tumor Treatment Market Share and Competitor Analysis

Pfizer Inc, Novartis AG, Ispen SA, Advanced Accelerator Applications, Inc., F. Hoffmann-La Roche Ltd., Amgen, Inc., Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, are among the key players in the neuroendocrine tumor treatment market.

Please note: This is not an exhaustive list of companies profiled in the report.

Chapter 1 Methodology

1.1 Market Scope & Definitions

1.2 Estimates & Forecast Calculation

1.3 Historical Data Overview and Validation

1.4 Data Sources

1.4.1 Secondary

1.4.2 Primary

Chapter 2 Report Outlook

2.1 Neuroendocrine Tumor Treatment Industry Overview, 2020-2026

2.1.1 Industry Overview

2.1.2 Product Overview

2.1.3 Site Overview

2.1.4 Route of Administration Overview

2.1.5 Indication Overview

2.1.6 End-User Overview

2.1.7 Regional Overview

Chapter 3 Neuroendocrine Tumor Treatment Market Trends

3.1 Market Segmentation

3.2 Industry Background, 2020-2026

3.3 Market Key Trends

3.3.1 Positive Trends

3.3.1.1 Rising incidence of neuroendocrine carcinoma

3.3.2 Industry Challenges

3.3.2.1 Lack of capital investment for the launch of novel drugs in developing region

3.4 Prospective Growth Scenario

3.4.1 Product Growth Scenario

3.4.2 Site Growth Scenario

3.4.3 Route of Administration Growth Scenario

3.4.4 Indication Growth Scenario

3.4.5 End-User Growth Scenario

3.5 COVID-19 Influence over Industry Growth

3.6 Porter’s Analysis

3.7 PESTEL Analysis

3.8 Value Chain & Supply Chain Analysis

3.9 Regulatory Framework

3.9.1 North America

3.9.2 Europe

3.9.3 APAC

3.9.4 LATAM

3.9.5 MEA

3.10 End-User Overview

3.11 Market Share Analysis, 2020

3.11.1 Company Positioning Overview, 2020

Chapter 4 Neuroendocrine Tumor Treatment Market, By Product

4.1 Product Outlook

4.2 Somatostatin Analog (SSAs)

4.2.1 Market Size, By Region, 2020-2026 (USD Billion)

4.3 Targeted Therapy

4.3.1 Market Size, By Region, 2020-2026 (USD Billion)

4.4 Chemotherapy

4.4.1 Market Size, By Region, 2020-2026 (USD Billion)

4.5 Others

4.5.1 Market Size, By Region, 2020-2026 (USD Billion)

Chapter 5 Neuroendocrine Tumor Treatment Market, By Route of Administration

5.1 Route of Administration Outlook

5.2 Oral

5.2.1 Market Size, By Region, 2020-2026 (USD Billion)

5.3 Parenteral

5.3.1 Market Size, By Region, 2020-2026 (USD Billion)

Chapter 6 Neuroendocrine Tumor Treatment Market, By Site

6.1 Lungs, Pancreas, Colon, Small Intestine, Others

6.1.1 Market Size, By Region, 2020-2026 (USD Billion)

6.2 Pancreas

6.2.1 Market Size, By Region, 2020-2026 (USD Billion)

6.3 Colon

6.2.1 Market Size, By Region, 2020-2026 (USD Billion)

6.4 Small Intestine

6.2.1 Market Size, By Region, 2020-2026 (USD Billion)

6.5 Others

6.2.1 Market Size, By Region, 2020-2026 (USD Billion)

Chapter 7 Neuroendocrine Tumor Treatment Market, By Indication

7.1 Lungs

7.1.1 Market Size, By Region, 2020-2026 (USD Billion)

7.2 Pancreas

7.2.1 Market Size, By Region, 2020-2026 (USD Billion)

7.3 Gastrointestinal

7.3.1 Market Size, By Region, 2020-2026 (USD Billion)

7.4 Others

7.4.1 Market Size, By Region, 2020-2026 (USD Billion)

Chapter 8 Neuroendocrine Tumor Treatment Market, By End-User

8.1 Hospitals

8.1.1 Market Size, By Region, 2020-2026 (USD Billion)

8.2 Specialty Clinics

8.2.1 Market Size, By Region, 2020-2026 (USD Billion)

8.3 Radiation Centers

8.3.1 Market Size, By Region, 2020-2026 (USD Billion)

8.4 Home Healthcare

8.4.1 Market Size, By Region, 2020-2026 (USD Billion)

8.5 Others

8.5.1 Market Size, By Region, 2020-2026 (USD Billion)

Chapter 9 Portable CPAP Systems Market, By Region

9.1 Regional outlook

9.2 North America

9.2.1 Market Size, By Country 2021-2026 (USD Billion)

9.2.2 Market Size, By Product, 2021-2026 (USD Billion)

9.2.3 Market Size, By Site, 2021-2026 (USD Billion)

9.2.4 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.2.5 Market Size, By Indication, 2021-2026 (USD Billion)

9.2.6 Market Size, By End-User, 2021-2026 (USD Billion)

9.2.7 U.S.

9.2.7.1 Market Size, By Product, 2021-2026 (USD Billion)

9.2.7.2 Market Size, By Site, 2021-2026 (USD Billion)

9.2.7.3 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.2.7.4 Market Size, By Indication, 2021-2026 (USD Billion)

9.2.7.5 Market Size, By End-User, 2021-2026 (USD Billion)

9.2.8 Canada

9.2.8.1 Market Size, By Product, 2021-2026 (USD Billion)

9.2.8.2 Market Size, By Site, 2021-2026 (USD Billion)

9.2.8.3 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.2.8.4 Market Size, By Indication, 2021-2026 (USD Billion)

9.2.8.5 Market Size, By End-User, 2021-2026 (USD Billion)

9.2.9 Mexico

9.2.9.1 Market Size, By Product, 2021-2026 (USD Billion)

9.2.9.2 Market Size, By Site, 2021-2026 (USD Billion)

9.2.9.3 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.2.9.4 Market Size, By Indication, 2021-2026 (USD Billion)

9.2.9.5 Market Size, By End-User, 2021-2026 (USD Billion)

9.3 Europe

9.3.1 Market Size, By Country 2021-2026 (USD Billion)

9.3.2 Market Size, By Product, 2021-2026 (USD Billion)

9.3.3 Market Size, By Site, 2021-2026 (USD Billion)

9.3.4 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.3.5 Market Size, By Indication, 2021-2026 (USD Billion)

9.3.6 Market Size, By End-User, 2021-2026 (USD Billion)

9.3.7 Germany

9.3.7.1 Market Size, By Product, 2021-2026 (USD Billion)

9.3.7.2 Market Size, By Site, 2021-2026 (USD Billion)

9.3.7.3 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.3.7.4 Market Size, By Indication, 2021-2026 (USD Billion)

9.3.7.5 Market Size, By End-User, 2021-2026 (USD Billion)

9.3.8 UK

9.3.8.1 Market Size, By Product, 2021-2026 (USD Billion)

9.3.8.2 Market Size, By Site, 2021-2026 (USD Billion)

9.3.8.3 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.3.8.4 Market Size, By Indication, 2021-2026 (USD Billion)

9.3.8.5 Market Size, By End-User, 2021-2026 (USD Billion)

9.3.9 France

9.3.9.1 Market Size, By Product, 2021-2026 (USD Billion)

9.3.9.2 Market Size, By Site, 2021-2026 (USD Billion)

9.3.9.3 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.3.9.4 Market Size, By Indication, 2021-2026 (USD Billion)

9.3.9.5 Market Size, By End-User, 2021-2026 (USD Billion)

9.3.10 Italy

9.3.10.1 Market Size, By Product, 2021-2026 (USD Billion)

9.3.10.2 Market Size, By Site, 2021-2026 (USD Billion)

9.3.10.3 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.3.10.4 Market Size, By Indication, 2021-2026 (USD Billion)

9.3.10.5 Market Size, By End-User, 2021-2026 (USD Billion)

9.4 Asia Pacific

9.4.1 Market Size, By Country 2021-2026 (USD Billion)

9.4.2 Market Size, By Product, 2021-2026 (USD Billion)

9.4.3 Market Size, By Site, 2021-2026 (USD Billion)

9.4.4 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.4.5 Market Size, By Indication, 2021-2026 (USD Billion)

9.4.6 Market Size, By End-User, 2021-2026 (USD Billion)

9.4.7 China

9.4.7.1 Market Size, By Product, 2021-2026 (USD Billion)

9.4.7.2 Market Size, By Site, 2021-2026 (USD Billion)

9.4.7.3 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.4.7.4 Market Size, By Indication, 2021-2026 (USD Billion)

9.4.7.5 Market Size, By End-User, 2021-2026 (USD Billion)

9.4.8 India

9.4.8.1 Market Size, By Product, 2021-2026 (USD Billion)

9.4.8.2 Market Size, By Site, 2021-2026 (USD Billion)

9.4.8.3 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.4.8.4 Market Size, By Indication, 2021-2026 (USD Billion)

9.4.8.5 Market Size, By End-User, 2021-2026 (USD Billion)

9.4.9 Japan

9.4.9.1 Market Size, By Product, 2021-2026 (USD Billion)

9.4.9.2 Market Size, By Site, 2021-2026 (USD Billion)

9.4.9.3 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.4.9.4 Market Size, By Indication, 2021-2026 (USD Billion)

9.4.9.5 Market Size, By End-User, 2021-2026 (USD Billion)

9.5 MEA

9.5.1 Market Size, By Country 2021-2026 (USD Billion)

9.5.2 Market Size, By Product, 2021-2026 (USD Billion)

9.5.3 Market Size, By Site, 2021-2026 (USD Billion)

9.5.4 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.5.5 Market Size, By Indication, 2021-2026 (USD Billion)

9.5.6 Market Size, By End-User, 2021-2026 (USD Billion)

9.5.7 Saudi Arabia

9.5.7.1 Market Size, By Product, 2021-2026 (USD Billion)

9.5.7.2 Market Size, By Site, 2021-2026 (USD Billion)

9.5.7.3 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.5.7.4 Market Size, By Indication, 2021-2026 (USD Billion)

9.5.7.5 Market Size, By End-User, 2021-2026 (USD Billion)

9.5.8 UAE

9.5.8.1 Market Size, By Product, 2021-2026 (USD Billion)

9.5.8.2 Market Size, By Site, 2021-2026 (USD Billion)

9.5.8.3 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.5.8.4 Market Size, By Indication, 2021-2026 (USD Billion)

9.5.8.5 Market Size, By End-User, 2021-2026 (USD Billion)

9.5.9 South Africa

9.5.9.1 Market Size, By Product, 2021-2026 (USD Billion)

9.5.9.2 Market Size, By Site, 2021-2026 (USD Billion)

9.5.9.3 Market Size, By Route of Administration, 2021-2026 (USD Billion)

9.5.9.4 Market Size, By Indication, 2021-2026 (USD Billion)

9.5.9.5 Market Size, By End-User, 2021-2026 (USD Billion)

Chapter 10 Company Landscape

10.1 Competitive Analysis, 2020

10.2 Pfizer Inc

10.2.1 Company Overview

10.2.2 Financial Analysis

10.2.3 Strategic Positioning

10.2.4 Info Graphic Analysis

10.3 Novartis AG

10.3.1 Company Overview

10.3.2 Financial Analysis

10.3.3 Strategic Positioning

10.3.4 Info Graphic Analysis

10.4 Ispen SA

10.4.1 Company Overview

10.4.2 Financial Analysis

10.4.3 Strategic Positioning

10.4.4 Info Graphic Analysis

10.5 Advanced Accelerator Applications

10.5.1 Company Overview

10.5.2 Financial Analysis

10.5.3 Strategic Positioning

10.5.4 Info Graphic Analysis

10.6 F. Hoffmann-La Roche Ltd

10.6.1 Company Overview

10.6.2 Financial Analysis

10.6.3 Strategic Positioning

10.6.4 Info Graphic Analysis

10.7 Amgen, Inc

10.7.1 Company Overview

10.7.2 Financial Analysis

10.7.3 Strategic Positioning

10.7.4 Info Graphic Analysis

10.8 Tarveda Therapeutics

10.10.1 Company Overview

10.10.2 Financial Analysis

10.10.3 Strategic Positioning

10.10.4 Info Graphic Analysis

10.11 Progenics Pharmaceuticals, Inc

10.10.1 Company Overview

10.10.2 Financial Analysis

10.10.3 Strategic Positioning

10.10.4 Info Graphic Analysis

10.10 Hutchison Medipharma Limited

10.10.1 Company Overview

10.10.2 Financial Analysis

10.10.3 Strategic Positioning

10.10.4 Info Graphic Analysis

10.11 Other Companies

10.11.1 Company Overview

10.11.2 Financial Analysis

10.11.3 Strategic Positioning

10.11.4 Info Graphic Analysis

The Global Neuroendocrine Tumor Treatment Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Neuroendocrine Tumor Treatment Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe. Privacy

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

What is the projected market size of the global neuroendocrine tumor treatment market?

The global neuroendocrine tumor treatment market is projected to grow from USD 1.8 billion in 2021 to USD 2.1 billion by 2026 at a CAGR value of 5.7% from 2021 to 2026.

Who are the major vendors in the neuroendocrine tumor treatment market?

Which region has the highest market share in the neuroendocrine tumor treatment market?

The North American region is estimated to hold the largest share of the neuroendocrine tumor treatment market.

What is the Covid-19 impact on the future of the neuroendocrine tumor treatment market?

What are the major drivers in the neuroendocrine tumor treatment market?